Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR7967)
Name
Entinostat
Synonyms
Entinostat; 209783-80-2; ms-275; SNDX-275; MS 275; MS-27-275; SNDX 275; Entinostat (MS-275); MS 27-275; pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate; MS275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; UNII-1ZNY4FKK9H; Entinostat (MS-275,SNDX-275); 1ZNY4FKK9H; BAY 86-5274; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; CHEMBL27759; pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; NSC706995; BAY86-5274; NSC-706995; N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester; pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate.; pyridin-3-ylmethyl N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate; Carbamic acid, N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Histone Deacetylase Inhibitor I; entinostatum; N-(2-aminophenyl)-4-[N-(pyridin-3-ylmethoxycarbonyl)aminomethyl]benzamide; Entinostat, free base; PubChem24433; Entinostat [USAN:INN]; MS-275 (Entinostat); MS-275 - Entinostat; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate; benzamide-type inhibitor, 3; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; cc-216; MLS006010183; Entinostat (JAN/USAN/INN); SCHEMBL148309; GTPL7007; DTXSID0041068; BDBM19410; AOB2570; EX-A038; SYN3039; CHEBI:132082; BCPP000155; HMS3426G07; HMS3648K12; HMS3654O11; HMS3744O17; ACT06782; AMY31163; BCP01824; MS-275,Entinostat,SNDX-275/; ZINC1488870; ABP000145; MFCD08272435; NSC756642; s1053; 3-pyridylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; AKOS024262667; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; AC-8968; BCP9000967; Carbamic acid, 3-pyridinylmethyl ester; CCG-208680; CS-0511; DB11841; Entinostat (MS-275, SNDX-275); NSC 706995; NSC-756642; SB16665; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; NCGC00165833-01; NCGC00165833-02; NCGC00165833-03; NCGC00165833-04; NCGC00165833-13; AK158952; AS-17906; Carbamic acid, N-((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3- pyridinylmethyl ester; HY-12163; MS27-275; NCI60_038022; SMR004458705; MS-275, A HDAC1 and HDAC3 inhibitor; AB0021206; MS-275-27; ZK 244894; FT-0667871; SW219667-1; V2451; EC-000.2117; D09338; W-5370; 48247-EP2298768A1; 48247-EP2305643A1; 48247-EP2308868A1; 48247-EP2311494A1; 48247-EP2311840A1; 783M802; A815057; MS-275,Entinostat, SNDX-275, MS-27-275; SR-01000946382; Q1281020; SR-01000946382-1; W-201831; BRD-K77908580-001-02-1; BRD-K77908580-001-04-7; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; [4-(2-Amino-phenylcarbamoyl)-benzyl]-carbamic acid pyridin-3-ylmethyl ester; N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]-3-pyridinylmethyl ester, carbamic acid; N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester; 442532-99-2
    Click to Show/Hide
Molecular Type
Small molecule
Disease Breast cancer [ICD-11: 2C60] Phase 3 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C21H20N4O3
PubChem CID
4261
Canonical SMILES
C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3
InChI
1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)
InChIKey
INVTYAOGFAGBOE-UHFFFAOYSA-N
CAS Number
CAS 209783-80-2
ChEBI ID
CHEBI:132082
TTD Drug ID
D0M8FD
DrugBank ID
DB11841
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Cladribine      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Up-regulation Cleavage CASP3  Molecule Info 
Pathway MAP
Up-regulation Cleavage CASP8  Molecule Info 
Pathway MAP
Up-regulation Cleavage CASP9  Molecule Info 
Pathway MAP
                    In-vitro Model RPMI-8226 CVCL_0014 Plasma cell myeloma Homo sapiens
U266B1 CVCL_0566 Plasma cell myeloma Homo sapiens
MM1.R CVCL_8794 Plasma cell myeloma Homo sapiens
                    Experimental
                    Result(s)
Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response.
Target and Pathway
Target(s) Histone deacetylase 1 (HDAC1)  Molecule Info  [3]
KEGG Pathway Cell cycle Click to Show/Hide
2 Notch signaling pathway
3 Thyroid hormone signaling pathway
4 Huntington's disease
5 Amphetamine addiction
6 Alcoholism
7 Epstein-Barr virus infection
8 Pathways in cancer
9 Transcriptional misregulation in cancer
10 Viral carcinogenesis
11 MicroRNAs in cancer
12 Chronic myeloid leukemia
NetPath Pathway TCR Signaling Pathway Click to Show/Hide
Panther Pathway Wnt signaling pathway Click to Show/Hide
2 p53 pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling Click to Show/Hide
2 Notch signaling pathway
3 E2F transcription factor network
4 Presenilin action in Notch and Wnt signaling
5 Signaling events mediated by HDAC Class I
6 Regulation of Telomerase
7 Glucocorticoid receptor regulatory network
8 Sumoylation by RanBP2 regulates transcriptional repression
9 Regulation of Androgen receptor activity
10 IL3-mediated signaling events
11 Validated nuclear estrogen receptor alpha network
12 Retinoic acid receptors-mediated signaling
13 Hedgehog signaling events mediated by Gli proteins
14 Regulation of nuclear beta catenin signaling and target gene transcription
15 Validated targets of C-MYC transcriptional repression
16 Regulation of retinoblastoma protein
17 Notch-mediated HES/HEY network
Reactome G0 and Early G1 Click to Show/Hide
2 p75NTR negatively regulates cell cycle via SC1
3 Formation of the beta-catenin:TCF transactivating complex
4 NOTCH1 Intracellular Domain Regulates Transcription
5 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
6 Constitutive Signaling by NOTCH1 PEST Domain Mutants
7 Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
8 HDACs deacetylate histones
9 Deactivation of the beta-catenin transactivating complex
10 NoRC negatively regulates rRNA expression
11 RNA Polymerase I Transcription Initiation
12 Factors involved in megakaryocyte development and platelet production
WikiPathways SIDS Susceptibility Pathways Click to Show/Hide
2 Notch Signaling Pathway
3 TGF beta Signaling Pathway
4 IL-6 signaling pathway
5 Apoptosis-related network due to altered Notch3 in ovarian cancer
6 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
7 Notch Signaling Pathway
8 Retinoblastoma (RB) in Cancer
9 Neural Crest Differentiation
10 TWEAK Signaling Pathway
11 Integrated Breast Cancer Pathway
12 Signalling by NGF
13 RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
14 Mitotic G1-G1/S phases
15 Factors involved in megakaryocyte development and platelet production
16 Cell Cycle
17 Androgen receptor signaling pathway
References
Reference 1 ClinicalTrials.gov (NCT03538171) Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer. U.S. National Institutes of Health.
Reference 2 Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. Cell Cycle. 2018;17(8):985-996.
Reference 3 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China